SCHEMBL4243025

SCHEMBL4243025

COc1ccc(S(=O)(=O)C(F)(F)F)cc1NC(C)=O

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.67
MEN1 O00255 5/20 0.67
ALDH1A1 P00352 3/20 0.54
ALDH3A1 P30838 1/20 0.52
LMNA P02545 3/20 0.51
RXFP1 Q9HBX9 2/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPK1 P28482 2/20 0.48
POLB P06746 1/20 0.48
HTT P42858 2/20 0.47
ALOX15 P16050 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241317 0.84 KMT2A (0.60) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL28417802 0.82 KMT2A (0.61) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL13294871 0.82 KMT2A (0.61) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL4240767 0.81 MAPT (0.61) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL11142183 0.81 CA1 (0.61) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL13556572 0.81 MEN1 (0.72) KMT2AMEN1ALDH1A1ALDH3A1LMNA
SCHEMBL30629806 0.81 CA1 (0.61) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL12916670 0.81 KMT2A (0.60) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL1553581 0.81 KMT2A (0.63) KMT2AMEN1ALDH1A1LMNARXFP1
SCHEMBL10891943 0.80 KMT2A (0.58) KMT2AMEN1ALDH1A1LMNARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US disclosed
US-7517880-B2 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517880-B2 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517880-B2 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHCARE LLC 2009-04-09 US disclosed
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHCARE LLC 2009-04-09 US disclosed
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed
EP-1616865-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas Bayer Pharmaceuticals Corporation (US) 2006-01-18 EP disclosed
EP-1042305-B1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER PHARMACEUTICALS CORP (US) 2005-06-08 EP disclosed
EP-1049664-B1 INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS BAYER PHARMACEUTICALS CORP (US) 2005-03-16 EP disclosed
EP-1449834-A2 Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas Bayer Corporation (US) 2004-08-25 EP disclosed
US-20040102636-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas BAYER CORPORATION 2004-05-27 US disclosed
EP-1042305-A4 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER AG (US) 2003-05-14 EP disclosed
EP-1049664-A1 INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS Bayer Corporation (US) 2000-11-08 EP disclosed
EP-1042305-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS Bayer Corporation (US) 2000-10-11 EP disclosed
WO-1999032436-A1 INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093526-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 KMT2A 2870/4885MEN1 4566/4885ALDH1A1 1875/4885
US-20040102636-A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas MAP2K2, MAPK1, MAP2K1 KMT2A 2870/4885MEN1 4566/4885ALDH1A1 1875/4885
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 KMT2A 2870/4885MEN1 4566/4885ALDH1A1 1875/4885
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas BRAF, RAF1, MAP2K2 KMT2A 1888/4885MEN1 3509/4885ALDH1A1 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.